美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Defiance Leveraged Long + Income HIMS ETF

5.43

0.0000

成交量：- -

成交额：- -

市值：271.36万

市盈率：- -

高：5.43

开：5.43

低：5.43

收：5.43

52周最高：28.09

52周最低：4.63

股本：50.00万

流通股本：50.00万

量比：- -

换手率：- -

股息：5.56

股息率：102.40%

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

3月10日美股成交额前20：HIMS与诺和诺德达成合作，股价大涨逾40%

环球市场播报

BUZZ--美国股票走势-Hims & Hers、Live Nation、NovaBridge

Hims与诺和诺德合作或引发短期逆风——市场快讯

FDA官员Makary表示欣慰：Hims将停止宣传未经批准的复方药物，转而通过与诺和诺德新合作销售FDA批准产品

诺和诺德与Hims & Hers达成协议，后者将销售Wegovy和Ozempic并撤销诉讼，股价延续涨势

诺和诺德确认将在HIMS & HERS平台上销售WEGOVY、OZEMPIC产品。

诺和诺德与Hims & Hers达成协议美国消费者可自费获取Ozempic注射剂与Wegovy口服/注射制剂

诺和诺德：撤回对Hims & Hers的专利侵权诉讼，但保留未来重新起诉权利

诺和诺德：Hims & Hers将停止在平台及营销中推广复合GLP-1产品

诺和诺德就 Hims 出售 Wegovy 和 Ozempic 达成协议，并撤销诉讼

Hims & Hers Health Inc.：计划在临床需要时提供复合GLP-1药物

据报导，诺和诺德（Novo Nordisk）与Hims公司的合作关系可能会结束法律纠纷，Hims公司股价随之大涨

Hims & Hers Health股价盘前暴涨37.9%，消息称诺和诺德将通过其平台销售减肥药

Hims & Hers Health盘后股价飙升39%，因报道称礼来与诺和诺德将合作销售减肥药

据彭博新闻社报导，诺和诺德与 Hims 解决纠纷，将共同销售肥胖症药物

诺和诺德和HIMS将共同销售减肥药，结束双方的争端。

BUZZ-Hims & Hers Health 下跌；摩根大通减持公司股份

摩根大通减持Hims & Hers Health股份，持股比例从8.1%降至1.7%

Strive Pharmacy 表示不会恢复复方口服司美格鲁肽的销售

据 Endpoints News 报道，Hims 的药房合作伙伴将重新推出从市场上撤下的 GLP-1 药片

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/HIMY/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HIMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIMY\",,,,,undefined,":{"symbol":"HIMY","market":"US","secType":"STK","nameCN":"Defiance Leveraged Long + Income HIMS ETF","latestPrice":5.4272,"timestamp":1773086400000,"preClose":5.4272,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":500000,"shares":500000,"eps":0,"marketStatus":"已收盘","change":0,"latestTime":"03-09 16:00:00 EDT","open":5.4272,"high":5.4272,"low":5.4272,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1773129600000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":5.4272,"sharesOutstanding":450000,"nav":5.39,"aum":2430000,"dividendRate":1.024009,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIMY\",,,,,undefined,":{"symbol":"HIMY","floatShares":500000,"roa":"--","roe":"--","lyrEps":0,"shares":500000,"dividePrice":5.5575,"high":5.4272,"amplitude":0,"preClose":5.4272,"low":5.4272,"week52Low":4.6299,"pbRate":"--","week52High":28.0918,"institutionHeld":0,"latestPrice":5.4272,"eps":0,"divideRate":1.024009,"volume":0,"delay":0,"ttmEps":0,"open":5.4272,"prevYearClose":6.5028,"prevWeekClose":5.4272,"prevMonthClose":5.4272,"prevQuarterClose":6.5028,"fiveDayClose":5.4272,"twentyDayClose":5.4272,"sixtyDayClose":9.9338},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HIMY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-01-27","symbol":"HIMY","reason":null,"defaultRemindTime":1769524200000,"announcedDate":"2026-01-26","type":"delisting","dateTimestamp":1769490000000},{"date":"2026-01-21","symbol":"HIMY","amount":0.0727,"announcedDate":"2026-01-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-21","defaultRemindTime":1769005800000,"name":"Defiance Leveraged Long + Income HIMS ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-22","payableDate":"2026-01-21","currency":"USD","dateTimestamp":1768971600000,"payDate":"2026-01-22"},{"date":"2026-01-14","symbol":"HIMY","amount":0.0725,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-14","defaultRemindTime":1768401000000,"name":"Defiance Leveraged Long + Income HIMS ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-15","payableDate":"2026-01-14","currency":"USD","dateTimestamp":1768366800000,"payDate":"2026-01-15"},{"date":"2026-01-07","symbol":"HIMY","amount":0.1045,"announcedDate":"2026-01-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-07","defaultRemindTime":1767796200000,"name":"Defiance Leveraged Long + Income HIMS ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2026-01-07","currency":"USD","dateTimestamp":1767762000000,"payDate":"2026-01-08"},{"date":"2025-12-31","symbol":"HIMY","amount":0.1087,"announcedDate":"2025-12-30","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-31","defaultRemindTime":1767191400000,"name":"Defiance Leveraged Long + Income HIMS ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-02","payableDate":"2025-12-31","currency":"USD","dateTimestamp":1767157200000,"payDate":"2026-01-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HIMY\",market:\"US\",,,undefined,":[{"executeDate":"2025-09-03","recordDate":"2025-09-03","paymentDate":"2025-09-04","value":0.2607,"currency":"USD"},{"executeDate":"2025-09-10","recordDate":"2025-09-10","paymentDate":"2025-09-11","value":0.3316,"currency":"USD"},{"executeDate":"2025-09-17","recordDate":"2025-09-17","paymentDate":"2025-09-18","value":0.3517,"currency":"USD"},{"executeDate":"2025-09-24","recordDate":"2025-09-24","paymentDate":"2025-09-25","value":0.5051,"currency":"USD"},{"executeDate":"2025-10-01","recordDate":"2025-10-01","paymentDate":"2025-10-02","value":0.5127,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HIMY\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HIMY\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618672446","title":"3月10日美股成交额前20：HIMS与诺和诺德达成合作，股价大涨逾40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672446","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618672446?lang=zh_cn&edition=fundamental","pubTime":"2026-03-10 04:48","pubTimestamp":1773089280,"startTime":"0","endTime":"0","summary":"周一美股成交额第1名英伟达收高2.72%，成交313.6亿美元。亿万富豪廖凯原周一再度增持英伟达，将其持股数量翻倍至200万股。　　摩尔维持对博通的“买入”评级，将其目标价从462美元上调至470美元，意味着约42%的上涨空间。　　此外，3月2日，英伟达宣布投资20亿美元并与Lumentum达成多年战略合作，包括数十亿美元采购高端激光元件的承诺，聚焦AI数据中心光学技术。　　该消息公布后，诺和诺德撤销了对该公司的诉讼，标志着双方争端的结束。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-10/doc-inhqmumf6558599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BKVL7J92.USD","BK4585","LU0154236417.USD","BK4599","BK4532","HIMS","NVO","HMYY","NVOH","BK4007","BK4196","LU1093756325.SGD","BK4588","NVOX","HIMY","HIMZ","IE00BZ1G4Q59.USD","HIYY","LU1093756168.USD"],"gpt_icon":1},{"id":"2618621524","title":"BUZZ--美国股票走势-Hims & Hers、Live Nation、NovaBridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621524","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618621524?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 21:30","pubTimestamp":1773063020,"startTime":"0","endTime":"0","summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4S3ZX1CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEM","RAPP","XOMO","UAL","AU","DTIL","HIMY","RLMD","PLD","LU1894683264.USD","HMYY","LU0162691827.USD","PFE","LU2462611646.USD","SATS","VRTL","AAL","BARC.UK","ITT","XOMX","HIMZ","VRT","NEMG","DAL","CAT","LU0170899867.USD","AALG","XOMZ","CDE","NBP","AGH","LYV","COP","HIMS","LITX","SLB","IE00B2Q91V27.USD","COHX","LU0433182093.SGD","LUV","SATG","HL","HIYY","XENE","FCEL","NWMX"],"gpt_icon":1},{"id":"1162171962","title":"Hims与诺和诺德合作或引发短期逆风——市场快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1162171962","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162171962?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 20:53","pubTimestamp":1773060828,"startTime":"0","endTime":"0","summary":"早盘8点49分——Hims & Hers Health Inc.股价因诺和诺德终止对其诉讼并达成合作的消息而大幅飙升。根据协议，Hims平台将引入诺和诺德的GLP-1类药物。Truist分析师指出，尽管此举消除了Hims面临的重要法律风险，但合作可能对其短期业务造成冲击。\n作为协议的一部分，Hims将停止销售复合GLP-1药物，而这类药物曾贡献其大部分营收。不过，品牌GLP-1药物的收入持续性显著更高，尤其考虑到Hims的复合药物此前一直面临法律威胁。分析师认为，这一转变可能促使投资者愿意给予Hims更高估值倍数。受此影响，Hims股价在盘前交易中猛涨51%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","IE00BKVL7J92.USD","HIYY","NVOH","HIMZ","BK4196","LU0154236417.USD","HIMS","BK4588","LU1093756168.USD","HIMY","BK4532","BK4585","BK4599","HMYY","NVOX","BK4007"],"gpt_icon":0},{"id":"1109539785","title":"FDA官员Makary表示欣慰：Hims将停止宣传未经批准的复方药物，转而通过与诺和诺德新合作销售FDA批准产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1109539785","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109539785?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 20:50","pubTimestamp":1773060649,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）官员Makary近日发表声明，对Hims & Hers Health Inc.决定停止推广未经批准的复方药物表示赞赏。该公司将转向通过与新合作伙伴诺和诺德（Novo）建立的合作关系，专门销售获得FDA正式批准的医药产品。\n这一战略调整标志着Hims在合规经营和产品质量管控方面迈出重要一步。通过采用经FDA严格审批的标准化药物，既能保障患者用药安全，又有助于提升企业品牌信誉。与诺和诺德的合作预计将拓宽其合规产品的市场覆盖范围。\n行业观察人士指出，此举可能对在线医疗平台的产品监管合规性产生示范效应。随着监管环境日趋严格，更多企业或将重新评估其复方药物的营销策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIYY","HMYY","HIMY","BK4196","HIMS","HIMZ"],"gpt_icon":0},{"id":"1127863922","title":"诺和诺德与Hims & Hers达成协议，后者将销售Wegovy和Ozempic并撤销诉讼，股价延续涨势","url":"https://stock-news.laohu8.com/highlight/detail?id=1127863922","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127863922?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 20:39","pubTimestamp":1773059964,"startTime":"0","endTime":"0","summary":"Hims & Hers Health Inc.  股价延续上涨态势，此前该公司与丹麦制药巨头诺和诺德达成合作协议，获得销售减肥药Wegovy和糖尿病药物Ozempic的授权。与此同时，诺和诺德已同意撤销对Hims & Hers提起的相关法律诉讼。分析人士指出，此次合作不仅解决了双方的法律纠纷，更为Hims & Hers打开了高达千亿美元的减肥药物市场大门。随着诺和诺德旗下明星产品Wegovy和Ozempic的加入，Hims & Hers的健康服务生态系统将得到进一步完善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIYY","HIMS","HIMZ","HIMY","BK4196","HMYY","NVO"],"gpt_icon":0},{"id":"2618356626","title":"诺和诺德确认将在HIMS & HERS平台上销售WEGOVY、OZEMPIC产品。","url":"https://stock-news.laohu8.com/highlight/detail?id=2618356626","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618356626?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 20:31","pubTimestamp":1773059515,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["HIMS","BK4196","BK4588","HMYY","IE00BZ1G4Q59.USD","LU0154236417.USD","HIYY","NVOH","BK4585","IE00BKVL7J92.USD","NVO","HIMZ","BK4599","BK4007","BK4532","HIMY","LU1093756325.SGD","NVOX","LU1093756168.USD"],"gpt_icon":0},{"id":"1146520715","title":"诺和诺德与Hims & Hers达成协议 美国消费者可自费获取Ozempic注射剂与Wegovy口服/注射制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1146520715","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146520715?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 20:31","pubTimestamp":1773059474,"startTime":"0","endTime":"0","summary":"根据最新合作协议，丹麦制药巨头诺和诺德与美国远程医疗平台Hims & Hers Health Inc.将共同为美国消费者开启新型减重疗法通道。消费者可通过自费方式获得诺和诺德旗下三款明星产品：Ozempic注射剂、Wegovy口服片剂及Wegovy注射剂。而Ozempic注射剂与Wegovy注射剂作为经过市场验证的成熟产品，将共同构成完整的体重管理解决方案。对于正在寻找替代传统分销渠道的诺和诺德而言，与Hims & Hers的合作或将开创代谢疾病管理的新范式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","HIYY","HMYY","HIMZ","HIMY","NVO","HIMS"],"gpt_icon":1},{"id":"1123143091","title":"诺和诺德：撤回对Hims & Hers的专利侵权诉讼，但保留未来重新起诉权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1123143091","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123143091?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 20:31","pubTimestamp":1773059467,"startTime":"0","endTime":"0","summary":"诺和诺德(Novo Nordisk)已正式撤回对数字健康平台Hims & Hers Health Inc.提起的专利侵权诉讼。不过，这家丹麦制药巨头同时明确表示，其保留在未来针对相同事由再次提起诉讼的权利。\n此次诉讼的撤回标志着双方现阶段法律交锋的暂告段落，但诺和诺德此举也为其后续可能采取的法律行动预留了空间。市场分析认为，这反映了诺和诺德在保护其核心产品知识产权方面的持续决心与灵活策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","NVO","HIYY","HIMS","HMYY","HIMZ","HIMY"],"gpt_icon":0},{"id":"1174808259","title":"诺和诺德：Hims & Hers将停止在平台及营销中推广复合GLP-1产品","url":"https://stock-news.laohu8.com/highlight/detail?id=1174808259","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174808259?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 20:31","pubTimestamp":1773059466,"startTime":"0","endTime":"0","summary":"诺和诺德宣布，数字健康平台Hims & Hers Health Inc.已同意全面停止在其平台及营销材料中推广复合GLP-1受体激动剂产品。这一决定标志着诺和诺德在维护其GLP-1药物市场主导地位方面取得重要进展。\nHims & Hers此前通过线上渠道提供复合版本的GLP-1类药物，这类产品通常未经严格监管审批。此次调整将有助于规范相关疗法市场，确保患者获得经临床验证的正规药物。\n作为全球GLP-1疗法领导者，诺和诺德始终致力于通过法律和技术手段保护其知识产权。该协议也反映出医药行业对数字化医疗平台合规性日益严格的监管趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","NVO","HIMY","HIYY","HIMZ","HMYY","HIMS"],"gpt_icon":0},{"id":"2618381626","title":"诺和诺德就 Hims 出售 Wegovy 和 Ozempic 达成协议，并撤销诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=2618381626","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618381626?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 20:30","pubTimestamp":1773059454,"startTime":"0","endTime":"0","summary":"诺和诺德就 Hims 出售 Wegovy 和 Ozempic 达成协议，并撤销诉讼Stine Jacobsen/Maggie Fick. 路透哥本哈根3月9日 - 丹麦制药商诺和诺德NOVb.CO周一表示，已同意通过美国远程医疗公司Hims & Hers的平台销售其重磅Wegovy和Ozempic药物，从而结束了上个月爆发的法律纠纷 。在这项交易之前，美国监管机构上周 ，警告30家远程医疗公司对包括Wegovy和Ozempic在内的GLP-1类复方药物进行误导性促销。诺和诺德表示，它将撤回诉讼，\"同时保留重新提起诉讼的权利\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4S3ZX181:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0158827781.USD","IE00B1XK9C88.USD","LU0882574139.USD","SG9999015986.USD","LU0109391861.USD","LU0823416689.USD","LU1720051108.HKD","SGXZ81514606.USD","GB00BDT5M118.USD","LU0432979614.USD","LLYZ","LU0683600562.USD","LU0689472784.USD","IE00BJJMRY28.SGD","LU1093756325.SGD","IE00B4JS1V06.HKD","LU1988902786.USD","SG9999018857.SGD","LLYX","LU1064131342.USD","IE00BKPKM429.USD","SG9999014880.SGD","LU0823434740.USD","HIMZ","BK4588","LU0079474960.USD","LU1145028129.USD","IE00B2B36J28.USD","LU0198837287.USD","IE00B7KXQ091.USD","SG9999017495.SGD","LU2361044865.SGD","LU1868836591.USD","LU0114720955.EUR","IE00BKDWB100.SGD","LU0820562030.AUD","IE0002141913.USD","LU2750360997.AUD","LU2417539215.USD","LU2750360641.GBP","LU2357305700.SGD","LU2756315664.SGD","BK4196","LU0289739699.SGD","LU2111349929.HKD","NVO","SG9999001176.USD","SG9999014914.USD","LU0943347566.SGD","LU1069344957.HKD","SGXZ51526630.SGD","LU1720051017.SGD","LU2456880835.USD","LU1623119135.USD","LU2108987350.USD","LU0672654240.SGD","LU0466842654.USD","LU1551013342.USD","BK4007","LU2168563687.JPY","LU2237443895.HKD","IE0004445239.USD","LU0096364046.USD","IE00BFSS7M15.SGD","LU1280957306.USD","LU2106854487.HKD","LU2360106947.USD","LU0266013472.USD","SGXZ31699556.SGD","BK4533","SG9999015978.USD","LU2552382215.SGD","LU0456855351.SGD","ELIL","LU2087625088.SGD","LU1057294990.SGD","LU2471134879.HKD","LU2089283258.USD","LU0964807845.USD","LU2237443465.HKD","LU2112291526.USD","LU0122379950.USD","LU1061106388.HKD","LU1291159041.SGD","LU1868836757.USD","LU1974910355.USD","LU2063271972.USD","LU2491050154.USD","IE0005OL40V9.USD","SG9999015945.SGD","LU2028103732.USD","IE00BFSS8Q28.SGD","BK4190","LU0058720904.USD","LU0786609619.USD","LU2168564065.EUR","LU0316494557.USD","LU1035775433.USD","LU0210536198.USD","IE00BK4W5L77.USD","LU0820561818.USD","LU1804176565.USD","LU1917777945.USD","LU2896262040.SGD","LU0417517546.SGD","IE00BJLML261.HKD","LU2237443549.SGD","LU1093756168.USD","LU2471134796.USD","LU0787776722.HKD","ELIS","LU0106261372.USD","LU0225283273.USD","HIMS","LU2237443382.USD","LU0256863902.USD","IE00BK4W5M84.HKD","LU1023059063.AUD","SG9999013999.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU2361044949.HKD","LU2471134952.CNY","BK4581","IE0004445015.USD","IE00BJJMRX11.SGD","LU2324357040.USD","LU2168564222.USD","LU1868836914.USD","LU2237443622.USD","HIMY","BK4599","LU0471298777.SGD","LU0320765992.SGD","LU2023251221.USD","LU0385154629.USD","LU2264538146.SGD","LU0353189763.USD","LU0354030438.USD","LU2211815571.USD","LU2756315318.SGD","LU2236285917.USD","LU1267930730.SGD","LU2461242641.AUD","LU0097036916.USD","LU0823434583.USD","LU1548497426.USD","LU1232071149.USD","SGXZ57979304.SGD","SG9999001176.SGD","BK4534","LU2361045086.USD","LU2491050071.SGD","LU0882574055.USD","LU2746668461.USD","SG9999014898.SGD","LU2602419157.SGD","LU1983299246.USD","HMYY","IE00BJJMRZ35.SGD","HIYY","LU0471298694.HKD","LU1814569148.SGD","LU0323591593.USD","LU0353189680.USD","LU0109394709.USD","LU2468319806.SGD","LU0889565916.HKD","LU0820561909.HKD","LU0203202063.USD","LU2552382058.USD","IE00BN29S564.USD","LU1127390331.HKD","LU2237438978.USD","LU2023250330.USD","IE00B1BXHZ80.USD","LU2265009873.SGD","LU1323610961.USD","LU0234572021.USD","LU2746668974.SGD","SGXZ99366536.SGD","LU2237443978.SGD","LU0640476718.USD","LU0354030511.USD","SG9999014906.USD","SG9999018865.SGD","IE0009355771.USD","LU0006306889.USD","LU0320765059.SGD","LU0708995401.HKD","SG9999015952.SGD","LU2089284900.SGD","LU2491049909.HKD","LU1868837136.USD","BK4516","LU2552382132.HKD","LU0203201768.USD","BK4585","LU2271345857.HKD","LU0061475181.USD","LU2213496289.HKD","LU2168564495.EUR","LU0158827948.USD","LU1551013425.SGD","LLII","LU0256863811.USD","LU0238689110.USD","LU2462157665.USD","IE00B775H168.HKD","LU1989771016.USD","LU1629891620.HKD","IE0001KFT4U8.USD","LU0094547139.USD","IE00B4R5TH58.HKD","LU2168564149.EUR","LU2471134523.USD","LU2023250504.SGD","LU1868837300.USD","LU1712237335.SGD","LU1366192091.USD","IE00BWXC8680.SGD","LU2089984988.USD"],"gpt_icon":1},{"id":"1130360019","title":"Hims & Hers Health Inc.：计划在临床需要时提供复合GLP-1药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1130360019","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130360019?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 20:30","pubTimestamp":1773059442,"startTime":"0","endTime":"0","summary":"Hims & Hers Health Inc. 宣布，若医疗服务提供者认定复合药物在临床上是必要的，公司计划提供获取复合GLP-1药物的途径。此举旨在根据专业医疗判断，为有特定需求的患者提供更多治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMY","HMYY","BK4196","HIYY","HIMS","HIMZ"],"gpt_icon":0},{"id":"2618647699","title":"据报导，诺和诺德（Novo Nordisk）与Hims公司的合作关系可能会结束法律纠纷，Hims公司股价随之大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647699","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647699?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 18:31","pubTimestamp":1773052273,"startTime":"0","endTime":"0","summary":"路透3月9日 - Hims & HersHIMS.N的股价周一盘前交易中上涨了50%以上，此前有报导称，诺和诺德公司NOVOb.CO计划在Hims & Hers的远程保健平台上销售其减肥药物，此举标志着两家公司之间的纠纷有可能结束。周五晚些时候，彭博新闻社报导了  诺和诺德与Hims准备宣布建立新的合作伙伴关系。不过，对Hims的财务影响仍不确定。去年，诺和诺德结束了一项短暂的协议 ，即通过Hims公司销售其Wegovy减肥药，原因是该公司的营销策略和继续销售Wegovy仿制药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4T3ZX0YM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMZ","HMYY","HIMY","HIMS","BK4196","HIYY"],"gpt_icon":1},{"id":"1113739733","title":"Hims & Hers Health股价盘前暴涨37.9%，消息称诺和诺德将通过其平台销售减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=1113739733","media":"美股速递","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113739733?lang=zh_cn&edition=fundamental","pubTime":"2026-03-09 16:11","pubTimestamp":1773043863,"startTime":"0","endTime":"0","summary":"远程医疗公司Hims & Hers Health Inc.股价在盘前交易时段飙升37.9%，表现异常强劲。这一显著上涨源于一则市场报告，该报告指出，制药巨头诺和诺德（Novo Nordisk）计划通过Hims & Hers Health的平台销售其广受欢迎的减肥药物。此举被视为对Hims & Hers业务模式的重要认可，并可能为其开辟巨大的新收入来源。投资者对此消息反应热烈，推动公司市值大幅增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMZ","HIYY","HMYY","HIMY","BK4196","HIMS"],"gpt_icon":0},{"id":"1157405095","title":"Hims & Hers Health盘后股价飙升39%，因报道称礼来与诺和诺德将合作销售减肥药","url":"https://stock-news.laohu8.com/highlight/detail?id=1157405095","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157405095?lang=zh_cn&edition=fundamental","pubTime":"2026-03-07 08:58","pubTimestamp":1772845133,"startTime":"0","endTime":"0","summary":"受到一则关于制药巨头将联手销售减肥药物的报道提振，Hims & Hers Health Inc.的股价在盘后交易时段录得惊人涨幅，飙升幅度高达39%。\n市场消息称，礼来公司与诺和诺德计划在肥胖症治疗药物领域展开合作，共同进行市场推广与销售。这一重磅合作传闻立即在投资者中引发强烈反响，显示出市场对减肥药市场巨大潜力的高度认可。\n作为一家专注于提供远程医疗服务和个性化健康解决方案的公司，Hims & Hers Health Inc.被市场视为减肥药物需求增长的重要受益者。投资者预期，行业领军企业的强强联合将进一步扩大市场规模，从而为Hims & Hers等相关企业带来显著的业务增长机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","HIYY","BK4196","HMYY","HIMS","HIMZ","HIMY"],"gpt_icon":0},{"id":"2617659381","title":"据彭博新闻社报导，诺和诺德与 Hims 解决纠纷，将共同销售肥胖症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2617659381","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617659381?lang=zh_cn&edition=fundamental","pubTime":"2026-03-07 08:56","pubTimestamp":1772844999,"startTime":"0","endTime":"0","summary":"据彭博新闻社报导，诺和诺德与 Hims 解决纠纷，将共同销售肥胖症药物路透3月7日 - 据彭博新闻社周五报导，Wegovy生产商诺和诺德NOVOb.CO计划在Hims & Hers HealthHIMS.N平台上销售其肥胖症药物，从而结束两家公司上个月升级为法律战的纠纷。报导援引一位熟悉内情的人士的话说，诺和诺德与Hims计划最快于下周一宣布新的合作关系。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260307:nL4T3ZV00V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIMZ","HIMY","HMYY","BK4196","NVO","HIYY","HIMS"],"gpt_icon":0},{"id":"2617262656","title":"诺和诺德和HIMS将共同销售减肥药，结束双方的争端。","url":"https://stock-news.laohu8.com/highlight/detail?id=2617262656","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617262656?lang=zh_cn&edition=fundamental","pubTime":"2026-03-07 08:34","pubTimestamp":1772843680,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4196","HIYY","NVO","BK4007","NVOH","BK4599","HIMZ","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4588","HIMY","HMYY","NVOX","LU0154236417.USD","BK4532","IE00BKVL7J92.USD","BK4585","HIMS","LU1093756325.SGD"],"gpt_icon":0},{"id":"2617273925","title":"BUZZ-Hims & Hers Health 下跌；摩根大通减持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2617273925","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617273925?lang=zh_cn&edition=fundamental","pubTime":"2026-03-06 01:43","pubTimestamp":1772732635,"startTime":"0","endTime":"0","summary":"3月5日 - ** 远程医疗公司Hims & Hers Health HIMS.N股价下跌3.8%至15.83美元** 截至2月27日的一份监管文件显示，华尔街巨头摩根大通JPM.N已将其在HIMS的持股比例从8.1%降至1.7%。** 包括本交易日在内，HIMS股价已下跌一半 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nL4S3ZT1RS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0323591593.USD","HIMS","IE000M9KFDE8.USD","LU0820561818.USD","LU0070302665.USD","LU1116320901.HKD","LU2430703251.USD","IE00BHPRN162.USD","LU0211331839.USD","LU1363072403.SGD","IE00B775SV38.USD","IE00B3S45H60.SGD","LU1280957306.USD","LU2417539215.USD","LU2237443549.SGD","LU0820562030.AUD","IE00BWXC8680.SGD","LU1032466523.USD","LU1116320737.USD","LU1974910355.USD","LU1119994496.HKD","LU0251132253.USD","LU0640476718.USD","HMYY","LU1244550494.USD","LU2242649171.HKD","IE00B1XK9C88.USD","LU0683600562.USD","HIMZ","LU0345770993.USD","LU1914381329.SGD","LU0787776722.HKD","LU1244550577.SGD","LU1162221912.USD","LU2236285917.USD","IE00BFXG1179.USD","LU2237443465.HKD","LU0345769631.USD","LU1720051017.SGD","LU2462157665.USD","IE00BN8TJ469.HKD","LU2023250330.USD","LU1894683264.USD","IE00B1BXHZ80.USD","LU0971096721.USD","SG9999002232.USD","IE00BBT3K403.USD","LU1668664300.SGD","IE00BZ1G4Q59.USD","LU1670627923.USD","LU0265550359.USD","LU0320765489.SGD","LU1894683348.USD","LU2505996681.GBP","LU0048584097.USD","LU1496350171.SGD","IE00BJLML261.HKD","BK4516","LU0215105999.USD","LU2211815571.USD","LU0820561909.HKD","LU2381873111.SGD","LU2456880835.USD","LU0942090050.USD","LU1670628061.USD","IE00BDCRKT87.USD","LU0345769128.USD","BK4550","LU0234572021.USD","LU2592432038.USD","IE0034235295.USD","LU0211328371.USD","LU0106261372.USD","LU2023250843.SGD","LU2552382058.USD","LU2237443978.SGD","IE00BKVL7J92.USD","LU2237443382.USD","LU1720051108.HKD","IE00BLSP4239.USD","IE00BJTD4V19.USD","LU0320765646.SGD","LU1548497426.USD","LU2106854487.HKD","LU2552382215.SGD","LU2357305700.SGD","JPMO","LU1551013425.SGD","LU0882574139.USD","LU0211327993.USD","LU0976567544.SGD","BK4534","LU2023250504.SGD","LU2430703095.HKD","LU1084165304.USD","LU1267930490.SGD","LU2552382132.HKD","LU2756315664.SGD","IE00BLSP4452.SGD","SG9999002224.SGD","BK4504","IE0034235303.USD","IE00BDRTCR15.USD","LU0238689110.USD","LU2213496289.HKD","LU2054465674.USD","BK4207","LU0256863811.USD","IE0034235188.USD","LU2264538146.SGD","LU2430703178.SGD","LU0943347566.SGD","IE00BJTD4N35.SGD","LU0006306889.USD","BK4588","LU1496350502.SGD","BK4566","LU2237443895.HKD","LU1551013342.USD","HIMY","HIYY","LU0211326839.USD","LU2505996509.AUD","LU2746668974.SGD","LU0868494617.USD","BK4581","LU0265550946.USD","BK4533","LU1629891620.HKD","LU0345770308.USD","LU0208291251.USD","LU0267386448.USD","LU0417517546.SGD","LU1366192091.USD","LU2237443622.USD","LU0868494708.USD","LU0689472784.USD","LU0310799852.SGD","BK4196","LU1145028129.USD","LU0203345920.USD","BK4585","LU2746668461.USD","LU1917777945.USD","LU0496365809.HKD","LU2756315318.SGD","IE00BYXW3230.USD","IE00BKDWB100.SGD","LU1244550221.USD","LU0203347892.USD","LU0964807845.USD","LU0149725797.USD","LU1988902786.USD","LU0211326755.USD","LU1064131342.USD","LU0106831901.USD","LU1261432733.SGD","LU0170899867.USD"],"gpt_icon":1},{"id":"1109675478","title":"摩根大通减持Hims & Hers Health股份，持股比例从8.1%降至1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109675478","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109675478?lang=zh_cn&edition=fundamental","pubTime":"2026-03-06 00:55","pubTimestamp":1772729752,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会（SEC）的文件显示，截至2026年2月27日，摩根大通（JPMorgan Chase & Co.）已将其在远程医疗服务提供商Hims & Hers Health Inc.的持股比例大幅削减至1.7%。这一数据相较于2025年9月30日记录的8.1%持股比例，出现了显著下降。\n此次减持行动反映了摩根大通对Hims & Hers Health投资策略的重大调整。持股比例在不到五个月内下降超过6个百分点，凸显出机构投资者对该股票的看法可能正在发生变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0323591593.USD","LU2237443622.USD","LU1629891620.HKD","IE00B3S45H60.SGD","IE00BDRTCR15.USD","LU1116320901.HKD","IE00BLSP4239.USD","LU1720051017.SGD","LU0203345920.USD","BK4534","IE0034235295.USD","IE00BJLML261.HKD","LU0310799852.SGD","LU0208291251.USD","IE00B775SV38.USD","LU0149725797.USD","LU0106831901.USD","LU0689472784.USD","LU2552382132.HKD","LU0234572021.USD","IE00B1BXHZ80.USD","LU0265550359.USD","BK4207","LU2552382058.USD","BK4504","IE00BLSP4452.SGD","LU0943347566.SGD","LU0683600562.USD","LU2381873111.SGD","LU1974910355.USD","LU2023250843.SGD","LU1032466523.USD","LU1084165304.USD","LU2430703178.SGD","LU2756315664.SGD","IE00BHPRN162.USD","LU1116320737.USD","IE0034235188.USD","LU2237443978.SGD","IE00BDCRKT87.USD","IE00BBT3K403.USD","LU0170899867.USD","LU1670628061.USD","BK4585","LU2264538146.SGD","BK4566","LU0971096721.USD","LU2592432038.USD","LU2237443382.USD","LU0820561909.HKD","LU0006306889.USD","LU0267386448.USD","BK4516","JPMO","LU0345769128.USD","LU1917777945.USD","LU1551013425.SGD","LU1363072403.SGD","LU1261432733.SGD","LU2237443465.HKD","LU2746668461.USD","LU2756315318.SGD","LU0882574139.USD","LU1267930490.SGD","LU2023250330.USD","LU1244550494.USD","LU0320765489.SGD","LU0211331839.USD","LU2213496289.HKD","LU2106854487.HKD","LU1894683348.USD","LU0496365809.HKD","SG9999002224.SGD","BK4550","LU0211328371.USD","LU0320765646.SGD","HIMS","IE00B1XK9C88.USD","LU0640476718.USD","LU2505996681.GBP","SG9999002232.USD","LU0211327993.USD","LU0238689110.USD","LU0265550946.USD","LU2552382215.SGD","IE00BZ1G4Q59.USD","LU2242649171.HKD","LU0345770308.USD","LU1162221912.USD","LU0345769631.USD","LU2505996509.AUD","LU0964807845.USD","LU1670627923.USD","LU1244550577.SGD","LU2236285917.USD","LU0868494617.USD","LU0215105999.USD","LU2054465674.USD","BK4533","LU0211326839.USD","IE0034235303.USD","LU0048584097.USD","IE00BKDWB100.SGD","LU2456880835.USD","BK4588","IE00BKVL7J92.USD","IE000M9KFDE8.USD","HIMY","IE00BFXG1179.USD","IE00BWXC8680.SGD","LU2237443549.SGD","LU2211815571.USD","IE00BYXW3230.USD","LU2023250504.SGD","LU1548497426.USD","LU2357305700.SGD","HMYY","LU1064131342.USD","BK4581","LU0211326755.USD","LU1145028129.USD","LU1496350171.SGD","LU0820562030.AUD","LU2237443895.HKD","LU0942090050.USD","LU1119994496.HKD","LU0976567544.SGD","LU2430703095.HKD","LU0820561818.USD","LU2462157665.USD","LU0417517546.SGD","JPM","LU1914381329.SGD","LU0787776722.HKD","BK4196","LU0868494708.USD","LU0070302665.USD","LU1496350502.SGD","IE00BN8TJ469.HKD","LU1720051108.HKD","LU0203347892.USD","LU1280957306.USD","LU1894683264.USD","LU2430703251.USD","LU2746668974.SGD","LU0251132253.USD","LU1366192091.USD","HIMZ","LU1244550221.USD","IE00BJTD4N35.SGD","LU1988902786.USD","LU0345770993.USD","LU0106261372.USD","LU1551013342.USD","IE00BJTD4V19.USD","LU0256863811.USD","HIYY","LU1668664300.SGD","LU2417539215.USD"],"gpt_icon":0},{"id":"2616022371","title":"Strive Pharmacy 表示不会恢复复方口服司美格鲁肽的销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2616022371","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616022371?lang=zh_cn&edition=fundamental","pubTime":"2026-03-04 05:12","pubTimestamp":1772572325,"startTime":"0","endTime":"0","summary":"更新版 1-Strive Pharmacy 表示不会恢复复方口服司美格鲁肽的销售改写全文以澄清 Strive 的回应，更新股份Mariam Sunny. Strive Pharmacy公司周二表示，它没有计划恢复诺和诺德NOVOb.CO口服司美格鲁肽复方制剂的销售，并反驳了早些时候媒体关于它将重新推出GLP-1药片的报导，此前美国监管机构对此表示担忧，该药片已被撤出市场。这家总部位于亚利桑那州的复方药房表示，它的药丸技术可用于多种活性成分，包括司美格鲁肽。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL4T3ZR20K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837136.USD","LU2552382215.SGD","LU0114720955.EUR","LU2089284900.SGD","LU2746668461.USD","SG9999014906.USD","SG9999015978.USD","LU1712237335.SGD","LU2462157665.USD","LU1291159041.SGD","LU2023251221.USD","LU2756315318.SGD","SG9999013999.USD","LU2471134796.USD","SG9999018857.SGD","LU0320765059.SGD","LU1267930730.SGD","SGXZ57979304.SGD","LU1814569148.SGD","BK4588","NVO","LU0820561818.USD","LU0006306889.USD","LU2063271972.USD","LU1323610961.USD","LU2213496289.HKD","LU2471134952.CNY","LU0820562030.AUD","LLYZ","ELIL","LU1917777945.USD","SGXZ99366536.SGD","LU0787776722.HKD","LU0316494557.USD","LU1623119135.USD","LU0689472784.USD","LU2168564065.EUR","LU2237443978.SGD","LU0786609619.USD","LU2417539215.USD","SG9999001176.USD","LU1035775433.USD","LU0943347566.SGD","LU2361044865.SGD","SG9999001176.SGD","IE00BK4W5L77.USD","LU0109394709.USD","LU0122379950.USD","LU0097036916.USD","LU1061106388.HKD","BK4196","LU2324357040.USD","LU2361044949.HKD","SG9999014898.SGD","LU0456855351.SGD","IE00BJJMRY28.SGD","IE00BJT1NW94.SGD","IE00BFSS8Q28.SGD","LU0640476718.USD","LU0820561909.HKD","LU1974910355.USD","LU2211815571.USD","LU0198837287.USD","LU0964807845.USD","IE00BFSS7M15.SGD","LU0708995401.HKD","IE00BWXC8680.SGD","LU2023250330.USD","IE00B1BXHZ80.USD","LU0385154629.USD","LLII","LU1366192091.USD","LU2237443622.USD","IE00BN29S564.USD","LU1551013342.USD","SG9999014914.USD","LU1280957306.USD","BK4581","LU1093756325.SGD","LU1720051108.HKD","LU0058720904.USD","IE00B4R5TH58.HKD","LU2108987350.USD","IE00BJLML261.HKD","IE00B775H168.HKD","LU2491050071.SGD","LU0683600562.USD","LU2456880835.USD","LU2237443895.HKD","LU0225283273.USD","SG9999015945.SGD","SG9999015986.USD","ELIS","LU0106261372.USD","LU0417517546.SGD","LU0158827781.USD","LU0061475181.USD","LU1868836914.USD","LLYX","IE00B1XK9C88.USD","LU0323591593.USD","LU2360106947.USD","LU0353189763.USD","LU1023059063.AUD","IE0002141913.USD","BK4533","LU1057294990.SGD","LU0079474960.USD","LU0203202063.USD","LU2236285917.USD","LU2023250504.SGD","LU1629891620.HKD","LU0889565916.HKD","LU2168564149.EUR","IE0005OL40V9.USD","LU1551013425.SGD","IE0004445239.USD","LU0823434583.USD","LU1127390331.HKD","LU2168564222.USD","IE0009355771.USD","LU2491050154.USD","LU1232071149.USD","LU1989771016.USD","LU2168564495.EUR","LU2264538146.SGD","LU2468319806.SGD","LU0466842654.USD","LU1868837300.USD","LU0203201768.USD","LU1069344957.HKD","IE00B4JS1V06.HKD","LU0158827948.USD","LU0823434740.USD","LU2237443382.USD","LU2756315664.SGD","IE00BK4W5M84.HKD","BK4516","LU0354030511.USD","IE00B2B36J28.USD","LU2112291526.USD","LU0289739699.SGD","LU0471298694.HKD","LU0882574055.USD","LU2237443549.SGD","LU2491049909.HKD","LU0096364046.USD","LU2602419157.SGD","SG9999018865.SGD","LU1720051017.SGD","BK4599","LU0432979614.USD","LU0266013472.USD","SGXZ31699556.SGD","LU0672654240.SGD","LU1804176565.USD","SG9999017495.SGD","LU0256863811.USD","LU1093756168.USD","HIMY","LU2089984988.USD","LU2471134523.USD","HIMZ","BK4534","LU2750360641.GBP","LU2265009873.SGD","LU0320765992.SGD","LU0210536198.USD","LU2089283258.USD","LU2461242641.AUD","LU0354030438.USD","LU0471298777.SGD","LU1064131342.USD","LU2106854487.HKD","LU2361045086.USD","IE00BKPKM429.USD","HIYY","LU0238689110.USD","HMYY","LU2028103732.USD","LU2168563687.JPY","SG9999014880.SGD","LU1988902786.USD","LU1145028129.USD","SG9999015952.SGD","LU0109391861.USD","LU2357305700.SGD","BK4007","LU2746668974.SGD","SGXZ81514606.USD","LU0353189680.USD","LU1868836757.USD","LU2237438978.USD","LU2552382058.USD","LU0256863902.USD","LU2750360997.AUD","IE00BFTCPJ56.SGD","HIMS","IE0004445015.USD","IE00BKDWB100.SGD","IE00BJJMRZ35.SGD","LU0094547139.USD","LU2552382132.HKD","SGXZ51526630.SGD","IE00BJJMRX11.SGD","LU0882574139.USD","LU2471134879.HKD","LU2087625088.SGD","IE00B7KXQ091.USD","LU1983299246.USD","BK4585","LU2271345857.HKD","LU1548497426.USD","LU1868836591.USD","IE0001KFT4U8.USD","LU0234572021.USD","LU2237443465.HKD","LU2896262040.SGD","GB00BDT5M118.USD","LU0823416689.USD","LU2111349929.HKD"],"gpt_icon":1},{"id":"2616525324","title":"据 Endpoints News 报道，Hims 的药房合作伙伴将重新推出从市场上撤下的 GLP-1 药片","url":"https://stock-news.laohu8.com/highlight/detail?id=2616525324","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616525324?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 23:34","pubTimestamp":1772552069,"startTime":"0","endTime":"0","summary":"路透3月3日 - 据Endpoints News周二报道，Hims & Hers Health的HIMS.N药房合作伙伴Strive Pharmacy在美国监管部门的反对下停止销售其复方减肥药后，计划通过其他医疗服务提供商恢复销售。报道援引对Hims药片背后的复方药房管理层的采访称，总部位于亚利桑那州的Strive公司尚未确定时间表，但将等待 \"一切尘埃落定后再重新推出\"。Strive和诺和诺德没有立即回应路透的置评请求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nL4S3ZR1K7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SGXZ99366536.SGD","LU2087625088.SGD","LU2491050154.USD","LU0096364046.USD","LU0640476718.USD","LU2106854487.HKD","LU2896262040.SGD","LU1267930730.SGD","LU1974910355.USD","LU2471134796.USD","LU0708995401.HKD","LLYZ","LU0320765992.SGD","SG9999014914.USD","IE00BK4W5L77.USD","LU2211815571.USD","LU2089984988.USD","LU2168564222.USD","LU2417539215.USD","LU2213496289.HKD","SGXZ57979304.SGD","LU1548497426.USD","SG9999014880.SGD","LU2461242641.AUD","LU2236285917.USD","LU0353189763.USD","LU0471298694.HKD","IE00BJJMRZ35.SGD","LU1035775433.USD","BK4534","LU0823434583.USD","LU2456880835.USD","SG9999014906.USD","LU1917777945.USD","BK4196","LU0061475181.USD","LU0683600562.USD","LU1983299246.USD","LU2552382215.SGD","LU0109394709.USD","LU0158827781.USD","IE00B4R5TH58.HKD","BK4007","LU2746668461.USD","LU0256863811.USD","LU0889565916.HKD","LU0787776722.HKD","LU2023250504.SGD","LU2361044949.HKD","LU0106261372.USD","LU2602419157.SGD","IE00B1BXHZ80.USD","LU0354030438.USD","HMYY","LU1868836914.USD","LU2237443622.USD","LU2168564149.EUR","ELIL","IE00BFSS8Q28.SGD","LU0823434740.USD","LU0786609619.USD","LU2756315664.SGD","BK4585","HIYY","LU0316494557.USD","SG9999015986.USD","SGXZ81514606.USD","LU1814569148.SGD","LU0256863902.USD","LU1868836591.USD","LU1989771016.USD","LU2552382132.HKD","LU2237443978.SGD","LU2324357040.USD","LU0823416689.USD","LU0109391861.USD","LU2168564495.EUR","LU1023059063.AUD","LU0385154629.USD","SG9999001176.USD","LU0122379950.USD","LU0158827948.USD","LU1291159041.SGD","IE00BFTCPJ56.SGD","LU0198837287.USD","IE00BJJMRX11.SGD","LU0432979614.USD","LU2028103732.USD","LU2168564065.EUR","IE00BWXC8680.SGD","LU0058720904.USD","LU0238689110.USD","LU0882574139.USD","BK4588","LU1145028129.USD","LU1804176565.USD","IE0005OL40V9.USD","LU0094547139.USD","LU0234572021.USD","LU2111349929.HKD","LU2491049909.HKD","LU2756315318.SGD","SG9999018865.SGD","IE00B7KXQ091.USD","LU2361044865.SGD","LU1093756168.USD","SG9999013999.USD","LU1551013425.SGD","LU2168563687.JPY","SG9999017495.SGD","LU0964807845.USD","LU1061106388.HKD","LU2264538146.SGD","LU2750360641.GBP","LU2271345857.HKD","IE00BKPKM429.USD","LU2112291526.USD","BK4599","LU1093756325.SGD","LLYX","BK4516","LU1064131342.USD","IE00BK4W5M84.HKD","LU0203201768.USD","IE0002141913.USD","IE0004445239.USD","LU2746668974.SGD","LU2237443382.USD","SG9999015952.SGD","IE0001KFT4U8.USD","LU2360106947.USD","HIMY","LU1720051108.HKD","LU2089283258.USD","IE00BJLML261.HKD","IE00BFSS7M15.SGD","SG9999018857.SGD","LU2265009873.SGD","SG9999014898.SGD","SGXZ51526630.SGD","IE00B2B36J28.USD","IE00BKDWB100.SGD","LU2237438978.USD","LU2237443549.SGD","LU2023250330.USD","LU2361045086.USD","IE0009355771.USD","LU1280957306.USD","LU0820561818.USD","IE0004445015.USD","LU1323610961.USD","LU2552382058.USD","LU1127390331.HKD","LU0225283273.USD","LU2471134879.HKD","LU0320765059.SGD","LU1069344957.HKD","ELIS","LU0210536198.USD","LU2750360997.AUD","LU0289739699.SGD","LU2471134952.CNY","LU0417517546.SGD","LU2491050071.SGD","LU2063271972.USD","HIMZ","LU1868837136.USD","LU2108987350.USD","LU0097036916.USD","BK4581","LU2237443465.HKD","LU0266013472.USD","IE00B4JS1V06.HKD","BK4533","LU1868837300.USD","SG9999015945.SGD","LU1988902786.USD","LU0354030511.USD","LU1057294990.SGD","LU2462157665.USD","IE00B775H168.HKD","LU2237443895.HKD","LU2471134523.USD","IE00BJT1NW94.SGD","LU0820561909.HKD","LU0820562030.AUD","LU1868836757.USD","SG9999001176.SGD","LU1366192091.USD","LU0323591593.USD","GB00BDT5M118.USD","LU1623119135.USD","SG9999015978.USD","LU0079474960.USD","LU1720051017.SGD","LU0882574055.USD","LLII","LU2089284900.SGD","IE00BJJMRY28.SGD","LU0353189680.USD","LU1629891620.HKD","LU0456855351.SGD","LU2468319806.SGD","IE00B1XK9C88.USD","LU0471298777.SGD","LU0114720955.EUR","LU0203202063.USD","LU0943347566.SGD","LU1232071149.USD","LU1551013342.USD","LU1712237335.SGD","SGXZ31699556.SGD","HIMS","LU0672654240.SGD","IE00BN29S564.USD","LU0689472784.USD","LU0006306889.USD","LU2023251221.USD","LU0466842654.USD","LU2357305700.SGD"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":47,"code":"91000000","status":"200"}]}}